356 related articles for article (PubMed ID: 22749793)
1. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
Kiwamoto T; Kawasaki N; Paulson JC; Bochner BS
Pharmacol Ther; 2012 Sep; 135(3):327-36. PubMed ID: 22749793
[TBL] [Abstract][Full Text] [Related]
2. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.
Bochner BS
Clin Exp Allergy; 2009 Mar; 39(3):317-24. PubMed ID: 19178537
[TBL] [Abstract][Full Text] [Related]
3. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand.
Tateno H; Crocker PR; Paulson JC
Glycobiology; 2005 Nov; 15(11):1125-35. PubMed ID: 15972893
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
[TBL] [Abstract][Full Text] [Related]
5. Discovery, Function, and Therapeutic Targeting of Siglec-8.
Youngblood BA; Leung J; Falahati R; Williams J; Schanin J; Brock EC; Singh B; Chang AT; O'Sullivan JA; Schleimer RP; Tomasevic N; Bebbington CR; Bochner BS
Cells; 2020 Dec; 10(1):. PubMed ID: 33374255
[TBL] [Abstract][Full Text] [Related]
6. An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.
Kerr SC; Gonzalez JR; Schanin J; Peters MC; Lambrecht BN; Brock EC; Charbit A; Ansel KM; Youngblood BA; Fahy JV
Clin Exp Allergy; 2020 Aug; 50(8):904-914. PubMed ID: 32542913
[TBL] [Abstract][Full Text] [Related]
7. Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.
O'Sullivan JA; Youngblood BA; Schleimer RP; Bochner BS
Semin Immunol; 2023 Sep; 69():101799. PubMed ID: 37413923
[TBL] [Abstract][Full Text] [Related]
8. "Siglec"ting the allergic response for therapeutic targeting.
Bochner BS
Glycobiology; 2016 Jun; 26(6):546-52. PubMed ID: 26911285
[TBL] [Abstract][Full Text] [Related]
9. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.
Youngblood BA; Brock EC; Leung J; Falahati R; Bochner BS; Rasmussen HS; Peterson K; Bebbington C; Tomasevic N
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465299
[TBL] [Abstract][Full Text] [Related]
10. Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.
O'Sullivan JA; Carroll DJ; Cao Y; Salicru AN; Bochner BS
J Allergy Clin Immunol; 2018 May; 141(5):1774-1785.e7. PubMed ID: 28734845
[TBL] [Abstract][Full Text] [Related]
11. The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.
Kiwamoto T; Katoh T; Tiemeyer M; Bochner BS
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):106-11. PubMed ID: 23160308
[TBL] [Abstract][Full Text] [Related]
12. A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells.
Nycholat CM; Duan S; Knuplez E; Worth C; Elich M; Yao A; O'Sullivan J; McBride R; Wei Y; Fernandes SM; Zhu Z; Schnaar RL; Bochner BS; Paulson JC
J Am Chem Soc; 2019 Sep; 141(36):14032-14037. PubMed ID: 31460762
[TBL] [Abstract][Full Text] [Related]
13. Siglec-8 and Siglec-F, the new therapeutic targets in asthma.
Farid SSh; Mirshafiey A; Razavi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):721-6. PubMed ID: 22324980
[TBL] [Abstract][Full Text] [Related]
14. Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.
Kiwamoto T; Katoh T; Evans CM; Janssen WJ; Brummet ME; Hudson SA; Zhu Z; Tiemeyer M; Bochner BS
J Allergy Clin Immunol; 2015 May; 135(5):1329-1340.e9. PubMed ID: 25497369
[TBL] [Abstract][Full Text] [Related]
15. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils.
Zimmermann N; McBride ML; Yamada Y; Hudson SA; Jones C; Cromie KD; Crocker PR; Rothenberg ME; Bochner BS
Allergy; 2008 Sep; 63(9):1156-63. PubMed ID: 18699932
[TBL] [Abstract][Full Text] [Related]
16. Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.
Knuplez E; Krier-Burris R; Cao Y; Marsche G; O'Sullivan J; Bochner BS
J Leukoc Biol; 2020 Jul; 108(1):43-58. PubMed ID: 32134149
[TBL] [Abstract][Full Text] [Related]
17. Siglecs as targets for therapy in immune-cell-mediated disease.
O'Reilly MK; Paulson JC
Trends Pharmacol Sci; 2009 May; 30(5):240-8. PubMed ID: 19359050
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement.
Yokoi H; Choi OH; Hubbard W; Lee HS; Canning BJ; Lee HH; Ryu SD; von Gunten S; Bickel CA; Hudson SA; Macglashan DW; Bochner BS
J Allergy Clin Immunol; 2008 Feb; 121(2):499-505.e1. PubMed ID: 18036650
[TBL] [Abstract][Full Text] [Related]
19. Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils.
O'Sullivan JA; Wei Y; Carroll DJ; Moreno-Vinasco L; Cao Y; Zhang F; Lee JJ; Zhu Z; Bochner BS
J Leukoc Biol; 2018 Jul; 104(1):11-19. PubMed ID: 29601103
[TBL] [Abstract][Full Text] [Related]
20. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice.
Youngblood BA; Brock EC; Leung J; Falahati R; Bryce PJ; Bright J; Williams J; Shultz LD; Greiner DL; Brehm MA; Bebbington C; Tomasevic N
Int Arch Allergy Immunol; 2019; 180(2):91-102. PubMed ID: 31401630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
